Remove Marketing Remove Pharma Companies Remove Regulation Remove Vaccine
article thumbnail

The drug industry continues to dare regulation

World of DTC Marketing

Pfizer expects to make as much as $22bn from its new Covid pill this year, on top of $37bn it made in 2021 from the vaccine. The study adds further evidence to the idea that drug copay cards are a great short-term deal for patients ā€” and especially the pharma companies that promote them ā€” but a wrong long-term value for healthcare costs.

article thumbnail

Can J&Jā€™s vaccine approval erase bad pharma?

World of DTC Marketing

SUMMARY: Pharma companies, like J&J, have received criticism for engaging in illegal activities, such as providing kickbacks and bribes, knowingly shipping adulterated or contaminated drugs to pharmacies, and marketing drugs for unapproved uses. Can a COVID-19 vaccine approval suddenly erase that? The answer is NO.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How pharma companies and governments can overcome COVID-19 vaccine hesitancy

BioPharma Reporter

While governments are now getting ready to ensure large-scale, equitable access and distribution of a COVID-19 vaccine, concern about vaccine hesitancy is growing worldwide. The COVID-19 pandemic is expected to continue to impose enormous burdens on societies and economies globally.

article thumbnail

COVID-19 vaccine equity: Campaigners say onus on pharma companies to start sharing IP and to transfer technology

BioPharma Reporter

Rows about vaccine supply and threats of export blocks donĆ¢t do anything to bring us closer to ending the COVID-19 pandemic, say campaigners pushing for vaccine equity on a global level.

article thumbnail

GSK flags new data suggesting a stark decline in routine adult vaccinations in the US

BioPharma Reporter

The pharma company and the CDC are recommending that adults continue routine vaccination during the COVID-19 pandemic to reduce future vaccine-preventable disease (VPD) outbreaks and overall strain on the healthcare system.

article thumbnail

Deep Dive: Market Access

pharmaphorum

Itā€™s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to work towards approving drugs and vaccines in record times, the sector is also facing an influx of digital therapeutics and advanced drugs that donā€™t fit neatly into existing access frameworks.

article thumbnail

Cyberattack targets EMA, hacks COVID-19 vaccine data

pharmaphorum

The European Medicines Agency (EMA) says it suffered a cyberattack, with documents relating to a Pfizer and BioNTechā€™s COVID-19 vaccine accessed. Shortly after however BioNTech confirmed that documents submitted as part of its marketing application for coronavirus vaccine BNT-162b had been accessed by the hackers.